论文部分内容阅读
目的探讨与胰腺癌发生、发展有密切关系的血清糖类抗原19-9(CA19-9)、糖类抗原242(CA242)以及癌胚抗原(CEA)等肿瘤标志物对于胰腺癌诊断的临床价值。方法 2010年5月至2012年5月,病理证实的30例胰腺癌患者为观察组,以同期30例健康体检者为对照组,采用RIA法,根据试剂盒操作要求,进行血清CA19-9、CA242以及CEA的检测。结果与对照组相比,观察组患者血清CA19-9、CA242以及CEA水平明显升高,差异有统计学意义(P<0.05)。肿瘤标志物单一诊断时,CA19-9的诊断价值相对较高,而CEA的诊断价值最差,而联合检测时,其敏感性达到93.3%,特异性为67.7%。结论血清CA19-9、CA242以及CEA等肿瘤标志物联合检测,可以为胰腺癌诊断提供特异性、高效的理论依据。
Objective To investigate the clinical value of tumor markers such as serum carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 242 (CA242) and carcinoembryonic antigen (CEA), which are closely related to the occurrence and development of pancreatic cancer, in the diagnosis of pancreatic cancer . Methods From May 2010 to May 2012, 30 patients with pathologically confirmed pancreatic cancer were selected as the observation group and 30 healthy people as the control group. The RIA method was used to determine the serum levels of CA19-9, CA242 and CEA testing. Results Compared with the control group, the levels of serum CA19-9, CA242 and CEA in observation group were significantly increased (P <0.05). The diagnostic value of CA19-9 is relatively high and the diagnostic value of CEA is the worst in the single diagnosis of tumor marker. The sensitivity and specificity of CA19-9 are 93.3% and 67.7%, respectively. Conclusions The combined detection of serum CA19-9, CA242 and CEA tumor markers can provide a specific and efficient theoretical basis for the diagnosis of pancreatic cancer.